Cale has Fanconi anemia, an ultra-rare blood disorder. At last count (when he was 7 years old) he had endured over 100 hospital stays and 26 surgeries. He thinks Creighton Blue Jays should win the NCAA tournament this year.
In the latest issue of the New England Journal Medicine, there is a report on the success of Bluebird Bio’s gene therapy for sickle cell disease.
This week in Thrombosis and Haemastasis, Pasi et al report on the long term safety and efficacy of Alprolix [Coagulation Factor IX (Recombinant), Fc Fusion Protein] in patients with severe hemophilia B.
Othon Iliopoulos, MD, of Massachusetts General Hospital describes Von Hippel-Lindau (VHL) Disease and the research his team is doing to better manage this rare condition.
TV and radio personality Alan Colmes died following a brief battle with lymphoma. Mr Colmes was 66 years old. It is uncertain what type of lymphoma he had.
At the 58th ASH meeting in San Diego, CA, we spoke with Dr. Marina Cavazzana PhD about the latest data on bluebird bio’s gene therapy to treat β-thalassemia and sickle cell disease.
Generex Biotechnology plans to buy 51% share of Emmaus Life Sciences, the company that recently submitted an NDA for L-glutamine to treat sickle cell disease.
David Miklos, MD of Stanford University talks about the use of ibrutinib in chronic graft versus host disease.
Saad Usmani, MD, FACP, of the Levine Cancer Institute talks about the convenience and safety of subcutaneous delivery of daratumumab in multiple myeloma patients.
Saad Usmani, MD, FACP, of the Levine Cancer Institute talks about very impressive data showing the efficacy of daratumumab, lenalidomide, and dexamethasone to treat relapsed or refractory multiple myeloma patients.